| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Protein Tyrosine Kinase/RTK (Receptor Tyrosine Kinase). Tephrosin is a natural product inhibitor of protein tyrosine kinases, disrupting the phosphorylation and activation of these key signaling enzymes involved in cell growth and survival.
|
|---|---|
| ln Vitro |
Applying tephrosin (0–10μM) to HT-29 cells prevents EGFR, ErbB2, and ErbB3 from being constitutively and ligand-phosphorylated. This also suppresses the activation of downstream signaling molecules like Akt and Erk1/2 mitogen-activated protein kinase (MAPK) [1].
Tephrosin is a natural rotenoid that has been identified as a protein tyrosine kinase inhibitor. Its mechanism of action involves blocking the activity of various receptor tyrosine kinases, which disrupts downstream signaling cascades such as the MAPK/ERK and PI3K/AKT pathways. This leads to the inhibition of cancer cell proliferation and the induction of apoptosis. |
| ln Vivo |
Tephrosin has been studied for its anti-cancer and anti-inflammatory properties in preclinical models. It has demonstrated the ability to inhibit the growth of various cancer cell lines and to reduce inflammatory responses. As a natural product, it serves as a chemical probe for studying the role of specific tyrosine kinases in disease pathophysiology.
|
| Enzyme Assay |
Cell-free protein tyrosine kinase assays are performed using a panel of recombinant human RTKs. The compound is incubated with an individual RTK, a peptide substrate, and ATP for 30-60 minutes. Kinase activity is measured using a luminescence-based ADP detection kit or a TR-FRET assay. The IC50 values against specific RTKs are determined.
|
| Cell Assay |
Cancer cell lines with high RTK expression are seeded in 96-well plates and treated with Tephrosin at concentrations ranging from 0.1 to 50 uM for 24-72 hours. Cell viability is assessed using the MTT assay. The effect on RTK phosphorylation and downstream signaling (p-ERK, p-AKT) is measured by Western blot. Apoptosis is assessed by Annexin V/PI staining.
|
| Animal Protocol |
For in vivo studies, Tephrosin would be administered to mice bearing tumor xenografts, typically by intraperitoneal injection. Dosing regimens and routes are not standardized and would depend on the specific formulation and solubility. Tumor volumes are measured with calipers. At study termination, tumors are excised for pharmacodynamic and histological analysis. No detailed protocols are available.
|
| ADME/Pharmacokinetics |
As a natural product, Tephrosin has a molecular weight of 410.42 (C23H22O7) and a CAS number of 76-80-2. It is soluble in DMSO (100 mg/mL) and ethanol. PK parameters such as oral bioavailability, half-life, and clearance have not been systematically characterized. Its stability in biological fluids is unknown. It is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for Tephrosin. As a natural rotenoid, its safety profile is not well-characterized. Rotenoids are generally considered toxic to insects and fish, and some can cause Parkinsonian symptoms in animal models at high doses. This compound is for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
Tephrosin belongs to the rotenone class of compounds, with the chemical formula 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromeno-7(7aH)-one, substituted with a geminal methyl group at position 3, a hydroxyl group at position 7a, and methoxy groups at positions 9 and 10 (7aR,13aR stereoisomers). It was isolated from the leaves and branches of Antheroporum pierrei and possesses antitumor and insecticidal activities. It can be used as an insecticide, an antitumor agent, and a metabolite. It is an organic heteropentacyclic compound, belonging to the aromatic ether, cyclic ketone, and rotenone class. Tephrosin has been reported to exist in Derris elliptica, Mundulea sericea, and several other organisms with relevant data.
Other information: Tephrosin (CAS 76-80-2) is a research-grade natural product, not an FDA-approved drug. It is a protein tyrosine kinase inhibitor and is used as a chemical probe to study RTK signaling. Its anti-cancer and anti-inflammatory properties make it a tool for drug discovery. Purity is typically ≥95-98%. Synonyms: Deguelinol I; Hydroxydeguelin. For research use only. |
| Molecular Formula |
C23H22O7
|
|---|---|
| Molecular Weight |
410.42
|
| Exact Mass |
410.136
|
| CAS # |
76-80-2
|
| Related CAS # |
Solidagolactone II;24399-43-7
|
| PubChem CID |
114909
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
623.4±55.0 °C at 760 mmHg
|
| Melting Point |
198° (218-220°)
|
| Flash Point |
219.3±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.614
|
| Source |
Originated from plants: Ranunculaceae Ranunculus japonicus Thunb.
|
| LogP |
4.48
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
30
|
| Complexity |
720
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1(C=CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@]4(C3=O)O)OC)OC)C
|
| InChi Key |
AQBZCCQCDWNNJQ-AUSIDOKSSA-N
|
| InChi Code |
InChI=1S/C23H22O7/c1-22(2)8-7-12-15(30-22)6-5-13-20(12)29-19-11-28-16-10-18(27-4)17(26-3)9-14(16)23(19,25)21(13)24/h5-10,19,25H,11H2,1-4H3/t19-,23-/m1/s1
|
| Chemical Name |
(1R,14R)-14-hydroxy-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (243.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4365 mL | 12.1826 mL | 24.3653 mL | |
| 5 mM | 0.4873 mL | 2.4365 mL | 4.8731 mL | |
| 10 mM | 0.2437 mL | 1.2183 mL | 2.4365 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
